Peptide Therapeutics Market Report by Type (Innovative, Generic), Type of Manufacturer (Outsourced, In-House), Synthesis Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, Hybrid Technology), Routes of Administration (Parenteral, O

Peptide Therapeutics Market Report by Type (Innovative, Generic), Type of Manufacturer (Outsourced, In-House), Synthesis Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, Hybrid Technology), Routes of Administration (Parenteral, Oral, and Others), Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Others), and Region 2023-2028


The global peptide therapeutics market size reached US$ 39.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 66.1 Billion by 2028, exhibiting a growth rate (CAGR) of 9.10% during 2022-2028.

Peptides are efficacious and selective signaling molecules that bind to specific cell surface receptors, such as ion channels and G protein-coupled receptors (GPCRs) and trigger intracellular effects. They are employed in the pharmaceutical industry to design novel regenerative therapeutics that can target a wide range of cells and manipulate their responses. These therapeutics are less toxic, relatively safe, and well-tolerated than other treatment options. As a result, they are gaining traction in clinical practices worldwide to manage cancer, injuries, infectious diseases, metabolic disorders, and aesthetic concerns.

Peptide Therapeutics Market Trends:
The growing prevalence of acute and chronic diseases, along with the rising access to medical facilities, represents one of the leading factors positively influencing the demand for peptides to develop innovative therapies. Moreover, peptides therapies are used in cosmeceutical surgeries to slow down the process of skin aging. This, coupled with the increasing consciousness among individuals about physical appearance and the desire to retain young and healthy skin, is driving the adoption of cosmetic surgeries and peptide therapeutics around the world. Apart from this, with the introduction of novel synthetic strategies that reduce injection frequency and improve stability and other physical properties, peptide therapeutics are widely being used in injections for diabetic patients. This, in confluence with the increasing incidence of diabetes and the growing preference for quick and precise treatment methods, is influencing the use of peptide therapeutics over oral medications. Furthermore, the emerging trend of personalized and targeted treatments is catalyzing the demand for multifunctional peptide-based materials. This, along with the rising funding to develop novel peptide therapeutics for treating autoimmune and inflammatory diseases, is projected to create a positive market outlook.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global peptide therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, type of manufacturer, synthesis technology, routes of administration and application.

Breakup by Type:

Innovative
Generic

Breakup by Type of Manufacturer:

Outsourced
In-house

Breakup by Synthesis Technology:

Solid Phase Peptide Synthesis
Liquid Phase Peptide Synthesis
Hybrid Technology

Breakup by Routes of Administration:

Parenteral
Oral
Others

Breakup by Application:

Gastrointestinal Disorders
Neurological Disorders
Metabolic Disorders
Cancer
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Apitope International NV, Arch Biopartners Inc., AstraZeneca plc, Circle Pharma Inc., Corden Pharma GmbH, F. Hoffmann-La Roche AG, Ipsen Group, Lonza Group AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Industries Ltd. and Zealand Pharma A/S.

Key Questions Answered in This Report
1. How big is the global peptide therapeutics market?
2. What is the expected growth rate of the global peptide therapeutics market during 2023-2028?
3. What are the key factors driving the global peptide therapeutics market?
4. What has been the impact of COVID-19 on the global peptide therapeutics market?
5. What is the breakup of the global peptide therapeutics market based on the type?
6. What is the breakup of the global peptide therapeutics market based on the type of manufacturer?
7. What is the breakup of the global peptide therapeutics market based on the synthesis technology?
8. What is the breakup of the global peptide therapeutics market based on the routes of administration?
9. What is the breakup of the global peptide therapeutics market based on the application?
10. What are the key regions in the global peptide therapeutics market?
11. Who are the key players/companies in the global peptide therapeutics market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Peptide Therapeutics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Innovative
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Generic
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Type of Manufacturer
7.1 Outsourced
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 In-house
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Synthesis Technology
8.1 Solid Phase Peptide Synthesis
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Liquid Phase Peptide Synthesis
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Hybrid Technology
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Routes of Administration
9.1 Parenteral
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Oral
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Application
10.1 Gastrointestinal Disorders
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Neurological Disorders
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Metabolic Disorders
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Cancer
10.4.1 Market Trends
10.4.2 Market Forecast
10.5 Others
10.5.1 Market Trends
10.5.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia-Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Amgen Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Apitope International NV
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.3 Arch Biopartners Inc.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.4 AstraZeneca plc
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.4.4 SWOT Analysis
16.3.5 Circle Pharma Inc.
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.6 Corden Pharma GmbH
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.7 F. Hoffmann-La Roche AG
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.7.3 SWOT Analysis
16.3.8 Ipsen Group
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 Lonza Group AG
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Novo Nordisk A/S
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.10.4 SWOT Analysis
16.3.11 Pfizer Inc.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
16.3.12 Teva Pharmaceuticals Industries Ltd.
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio
16.3.12.3 Financials
16.3.12.4 SWOT Analysis
16.3.13 Zealand Pharma A/S
16.3.13.1 Company Overview
16.3.13.2 Product Portfolio
16.3.13.3 Financials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings